Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.60 |
| ▸ | HTR7 | P34969 | 3/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | HRH1 | P35367 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.60 |
| ▸ | HTR2B | P41595 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | HRH2 | P25021 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3562685 | 0.93 | KDM4E (0.65) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| Fumaric Acid SCHEMBL3562688 | 0.93 | KDM4E (0.65) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL5809604 | 0.89 | DRD2 (0.46) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL5329365 | 0.87 | DRD2 (0.46) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL5563082 | 0.86 | HTR2A (0.46) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL21641980 | 0.86 | ADRA2A (0.54) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL19520604 | 0.82 | DRD2 (0.53) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL3126899 | 0.80 | DRD2 (0.40) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL4787337 | 0.78 | DRD2 (0.44) | DRD2HTR2AADRA2AADRA2BADRA2C | |
| SCHEMBL5971750 | 0.77 | MAPT (0.55) | DRD2HTR2AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589008-B1 | A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent | ASTRAZENECA AB (SE) | 2011-01-19 | — | — | EP | claimed |
| EP-1781646-A4 | PROCESS FOR THE PREPARATION OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-I-PIPERAZINYL)DIBENZO[B,F][1,4]THIAZEPINE | SK HOLDINGS CO LTD (KR) | 2009-03-04 | — | — | EP | claimed |
| EP-1951256-A1 | QUETIAPINE IN A CONTROLLED RELEASE FORMULATION | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | claimed |
| WO-2007058593-A1 | QUETIAPINE IN A CONTROLLED RELEASE FORMULATION | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | claimed |
| EP-1781646-A1 | PROCESS FOR THE PREPARATION OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-I-PIPERAZINYL)DIBENZO[B,F][1,4]THIAZEPINE | SK Corporation (KR) | 2007-05-09 | — | — | EP | claimed |
| WO-2006135544-A1 | SYNTHESIS OF 11-(4[-(2-HYDROXYETHOXY)ETHYL]-PIPERAZINYL)-DIBENZO[b,f][1,4]THIAZEPINE AND ITS FUMARATE SALT | CAMBREX CHARLES CITY, INC. (US) | 2006-12-21 | — | — | WO | claimed |
| WO-2006027789-A1 | PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JUBILANT ORGANOSYS LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| WO-2006001619-A1 | PROCESS FOR THE PREPARATION OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-I-PIPERAZINYL)DIB ENZO[b,f][l,4]THIAZEPINE | SK CORPORATION (KR) | 2006-01-05 | — | — | WO | claimed |
| EP-1448169-A1 | METHOD FOR IMPROVING DISSOLUTION OF POORLY DISPERSIBLE MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-25 | — | — | EP | claimed |
| WO-2003039516-A1 | METHOD FOR IMPROVING DISSOLUTION OF POORLY DISPERSIBLE MEDICAMENTS | FUJISAWA PHARMACEUTICLA CO., LTD. (JP) | 2003-05-15 | — | — | WO | claimed |
| US-20020147186-A1 | Crystalline dibenzothiazepine derivative and its use as an antipsychotic agent | ZENECA LIMITED | 2002-10-10 | — | — | US | claimed |
| EP-1218009-A1 | QUETIAPINE GRANULES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001021179-A1 | QUETIAPINE GRANULES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | claimed |
| EP-1000043-A1 | A CRYSTALLINE DIBENZOTHIAZEPINE DERIVATIVE AND ITS USE AS AN ANTIPSYCHOTIC AGENT | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | claimed |
| EP-0907364-A1 | PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1999-04-14 | — | — | EP | claimed |
| WO-1999006381-A1 | A CRYSTALLINE DIBENZOTHIAZEPINE DERIVATIVE AND ITS USE AS AN ANTIPSYCHOTIC AGENT | ZENECA LIMITED (GB) | 1999-02-11 | — | — | WO | claimed |
| WO-1997045124-A1 | PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1997-12-04 | — | — | WO | claimed |
| US-20240342189-A1 | ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY | TLC THERAPEUTICS LLC (US) | 2024-10-17 | — | — | US | disclosed |
| WO-1999006381-A1 | A CRYSTALLINE DIBENZOTHIAZEPINE DERIVATIVE AND ITS USE AS AN ANTIPSYCHOTIC AGENT | ZENECA LIMITED (GB) | 1999-02-11 | — | — | WO | disclosed |
| WO-1997045124-A1 | PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147186-A1 | Crystalline dibenzothiazepine derivative and its use as an antipsychotic agent | GRIN2D, CYP2F1, GRIN2C | DRD2 106/4885HTR2A 112/4885ADRA2A 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.